Previous Close | 16.20 |
Open | 16.58 |
Bid | 15.50 x 800 |
Ask | 18.25 x 900 |
Day's Range | 16.58 - 17.00 |
52 Week Range | 6.20 - 22.58 |
Volume | |
Avg. Volume | 1,638 |
Market Cap | 31.526M |
Beta (5Y Monthly) | 1.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.60 (4.00%) |
Ex-Dividend Date | Jul 20, 2023 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP
Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call: